Testosterone and prostate cancer: An evidence-based review of pathogenesis and oncologic risk

Jason E. Michaud, Kevin Lenuell Billups, Alan Wayne Partin

Research output: Contribution to journalArticle

Abstract

Testosterone plays a central role in male development and health. Likewise, androgen deficiency, or hypogonadism, is associated with a variety of symptoms including decreased energy, diminished libido and erectile dysfunction, among others. Male androgen levels steadily decline with age, and, in a subset of symptomatic older men, can result in late-onset hypogonadism (LOH). Over the last decade, increased awareness of hypogonadism among patients and providers has led to a significant rise in the use of testosterone replacement therapy (TRT) for hypogonadism, and especially in LOH. Accompanying the rise in TRT are concerns of potential adverse effects, including cardiovascular risks and the promotion of prostate cancer. The 'androgen hypothesis' asserts that prostate cancer development and progression is driven by androgens, and thus TRT has the theoretical potential to drive prostate cancer development and progression. In this review, we examine existing data surrounding testosterone and prostate cancer. There is significant evidence that androgens promote prostate cancer in experimental systems. However, there is no clear evidence that elevations in endogenous testosterone levels promote the development of prostate cancer in humans. As a result of experimental and historical data on the progression of prostate cancer following TRT, there has been widespread belief that TRT will promote disease progression in prostate cancer patients. Despite these fears, there are a growing number of studies demonstrating no increase in prostate cancer incidence among men on TRT. Furthermore, in studies involving a small number of patients, there has been no discernable increase in disease progression in prostate cancer patients on TRT. While data from large, prospective, randomized, controlled trials are absent, TRT in select prostate cancer patients is likely safe. In the end, the use of TRT in prostate cancer patients is still considered experimental and should only be offered after well-informed shared decision making and with close monitoring.

Original languageEnglish (US)
Pages (from-to)378-387
Number of pages10
JournalTherapeutic Advances in Urology
Volume7
Issue number6
DOIs
StatePublished - Dec 1 2015

Fingerprint

Testosterone
Prostatic Neoplasms
Hypogonadism
Androgens
Therapeutics
Disease Progression
Libido
Erectile Dysfunction
Fear
Decision Making
Randomized Controlled Trials
Incidence
Health

Keywords

  • hypogonadism
  • prostate cancer
  • testosterone

ASJC Scopus subject areas

  • Urology

Cite this

Testosterone and prostate cancer : An evidence-based review of pathogenesis and oncologic risk. / Michaud, Jason E.; Billups, Kevin Lenuell; Partin, Alan Wayne.

In: Therapeutic Advances in Urology, Vol. 7, No. 6, 01.12.2015, p. 378-387.

Research output: Contribution to journalArticle

@article{168ff73179a547dbbf9452655be80e62,
title = "Testosterone and prostate cancer: An evidence-based review of pathogenesis and oncologic risk",
abstract = "Testosterone plays a central role in male development and health. Likewise, androgen deficiency, or hypogonadism, is associated with a variety of symptoms including decreased energy, diminished libido and erectile dysfunction, among others. Male androgen levels steadily decline with age, and, in a subset of symptomatic older men, can result in late-onset hypogonadism (LOH). Over the last decade, increased awareness of hypogonadism among patients and providers has led to a significant rise in the use of testosterone replacement therapy (TRT) for hypogonadism, and especially in LOH. Accompanying the rise in TRT are concerns of potential adverse effects, including cardiovascular risks and the promotion of prostate cancer. The 'androgen hypothesis' asserts that prostate cancer development and progression is driven by androgens, and thus TRT has the theoretical potential to drive prostate cancer development and progression. In this review, we examine existing data surrounding testosterone and prostate cancer. There is significant evidence that androgens promote prostate cancer in experimental systems. However, there is no clear evidence that elevations in endogenous testosterone levels promote the development of prostate cancer in humans. As a result of experimental and historical data on the progression of prostate cancer following TRT, there has been widespread belief that TRT will promote disease progression in prostate cancer patients. Despite these fears, there are a growing number of studies demonstrating no increase in prostate cancer incidence among men on TRT. Furthermore, in studies involving a small number of patients, there has been no discernable increase in disease progression in prostate cancer patients on TRT. While data from large, prospective, randomized, controlled trials are absent, TRT in select prostate cancer patients is likely safe. In the end, the use of TRT in prostate cancer patients is still considered experimental and should only be offered after well-informed shared decision making and with close monitoring.",
keywords = "hypogonadism, prostate cancer, testosterone",
author = "Michaud, {Jason E.} and Billups, {Kevin Lenuell} and Partin, {Alan Wayne}",
year = "2015",
month = "12",
day = "1",
doi = "10.1177/1756287215597633",
language = "English (US)",
volume = "7",
pages = "378--387",
journal = "Therapeutic Advances in Urology",
issn = "1756-2872",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Testosterone and prostate cancer

T2 - An evidence-based review of pathogenesis and oncologic risk

AU - Michaud, Jason E.

AU - Billups, Kevin Lenuell

AU - Partin, Alan Wayne

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Testosterone plays a central role in male development and health. Likewise, androgen deficiency, or hypogonadism, is associated with a variety of symptoms including decreased energy, diminished libido and erectile dysfunction, among others. Male androgen levels steadily decline with age, and, in a subset of symptomatic older men, can result in late-onset hypogonadism (LOH). Over the last decade, increased awareness of hypogonadism among patients and providers has led to a significant rise in the use of testosterone replacement therapy (TRT) for hypogonadism, and especially in LOH. Accompanying the rise in TRT are concerns of potential adverse effects, including cardiovascular risks and the promotion of prostate cancer. The 'androgen hypothesis' asserts that prostate cancer development and progression is driven by androgens, and thus TRT has the theoretical potential to drive prostate cancer development and progression. In this review, we examine existing data surrounding testosterone and prostate cancer. There is significant evidence that androgens promote prostate cancer in experimental systems. However, there is no clear evidence that elevations in endogenous testosterone levels promote the development of prostate cancer in humans. As a result of experimental and historical data on the progression of prostate cancer following TRT, there has been widespread belief that TRT will promote disease progression in prostate cancer patients. Despite these fears, there are a growing number of studies demonstrating no increase in prostate cancer incidence among men on TRT. Furthermore, in studies involving a small number of patients, there has been no discernable increase in disease progression in prostate cancer patients on TRT. While data from large, prospective, randomized, controlled trials are absent, TRT in select prostate cancer patients is likely safe. In the end, the use of TRT in prostate cancer patients is still considered experimental and should only be offered after well-informed shared decision making and with close monitoring.

AB - Testosterone plays a central role in male development and health. Likewise, androgen deficiency, or hypogonadism, is associated with a variety of symptoms including decreased energy, diminished libido and erectile dysfunction, among others. Male androgen levels steadily decline with age, and, in a subset of symptomatic older men, can result in late-onset hypogonadism (LOH). Over the last decade, increased awareness of hypogonadism among patients and providers has led to a significant rise in the use of testosterone replacement therapy (TRT) for hypogonadism, and especially in LOH. Accompanying the rise in TRT are concerns of potential adverse effects, including cardiovascular risks and the promotion of prostate cancer. The 'androgen hypothesis' asserts that prostate cancer development and progression is driven by androgens, and thus TRT has the theoretical potential to drive prostate cancer development and progression. In this review, we examine existing data surrounding testosterone and prostate cancer. There is significant evidence that androgens promote prostate cancer in experimental systems. However, there is no clear evidence that elevations in endogenous testosterone levels promote the development of prostate cancer in humans. As a result of experimental and historical data on the progression of prostate cancer following TRT, there has been widespread belief that TRT will promote disease progression in prostate cancer patients. Despite these fears, there are a growing number of studies demonstrating no increase in prostate cancer incidence among men on TRT. Furthermore, in studies involving a small number of patients, there has been no discernable increase in disease progression in prostate cancer patients on TRT. While data from large, prospective, randomized, controlled trials are absent, TRT in select prostate cancer patients is likely safe. In the end, the use of TRT in prostate cancer patients is still considered experimental and should only be offered after well-informed shared decision making and with close monitoring.

KW - hypogonadism

KW - prostate cancer

KW - testosterone

UR - http://www.scopus.com/inward/record.url?scp=84947255712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947255712&partnerID=8YFLogxK

U2 - 10.1177/1756287215597633

DO - 10.1177/1756287215597633

M3 - Article

C2 - 26622322

AN - SCOPUS:84947255712

VL - 7

SP - 378

EP - 387

JO - Therapeutic Advances in Urology

JF - Therapeutic Advances in Urology

SN - 1756-2872

IS - 6

ER -